Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

BACKGROUND: Symptoms and comorbidities of ankylosing spondylitis (AS) considerably reduce health-related quality of life (HRQoL) and ability to work. This real-world study assessed rates of tumour necrosis factor inhibitor (TNFi) use and switching, treatment failure, and associations between failing...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, A., Strand, V., Conaghan, P. G., Sullivan, E., Blackburn, S., Tian, H., Gandhi, K., Jugl, S. M., Alten, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050131/
https://www.ncbi.nlm.nih.gov/pubmed/32159075
http://dx.doi.org/10.1186/s41927-020-0118-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050131/
https://www.ncbi.nlm.nih.gov/pubmed/32159075
http://dx.doi.org/10.1186/s41927-020-0118-z

Ejemplares similares